- Roth’s Healthcare Private Company Forum is currently taking place
- The investor-focused forum will feature a series of corporate fireside chats
- The conference will also play host to three investment panels
Today,
Roth Capital Partners (“Roth”) is hosting the Virtual Healthcare Private Company Forum. The event, which is now fully underway, features a number of different healthcare companies drawn from across the biotechnology, pharmaceuticals, and medical technologies verticals.
Roth has long been renowned for their experience and ever-growing network within the global healthcare industry, having been involved in more than 530 transactions for its healthcare clients since 2010, with a total transaction value of upwards of $24 billion. With the medical industry and emerging therapeutics sector evolving at a break-neck pace, Roth has sought to host the Healthcare Private Company Forum, providing executive management teams representing established private healthcare companies from across the medical industry an invaluable opportunity to meet and share their respective stories with attendees.
“We are excited to host our Virtual Healthcare Private Company Forum for private companies. As the event continues to grow, we are bringing together a broader range of private healthcare companies, from across the US and beyond, to tell their stories,” said James Antonopoulos, Managing Director & Head of Healthcare Investment Banking at Roth. “This event is another example of Roth’s continued leadership in supporting the growth of healthcare companies, including biotechnology, specialty pharmaceuticals, medical devices & diagnostics.”
The Roth conference will feature a series of fireside chats, with companies set to address a series of pertinent topics relating to the field of emerging therapeutics. These will include:
- Active Motif: “Enabling Tools and Services for Epigenetics and Gene Regulation Research”
- Aruna Bio: “Utilizing Exosomes to Cross the Blood/Brain”
- Cullgen: “Powering Protein Degradation for Tomorrow’s Medicines”
- Dyve Biosciences: “Breakthrough Drug Delivery Technology Expands Transdermal Therapeutic Options”
- Intensity Therapeutics: “Unprecedented Improvement Upon Intratumoral Injection”
- Reva Medical: “Bioresorbable Polymer Technologies for Vascular Applications”
- Ryvu Therapeutics: “Novel Small Molecule Therapies Addressing High-Value Oncology Indications”
Moreover, the conference will also play host to three discussion panels, featuring leading companies involved within the respective sectors and moderated by Roth research analysts. The panels will touch upon topics such as “Novel Approaches to Tumor Eradication”; “Natural Killer Cell Approaches to Eradicate Tumors”, and the “Next Wave of Psychedelic Drug Developers.”
By showcasing some of the industry’s most cutting-edge and privately held companies, Roth Virtual Healthcare Private Company Forum is providing attendees with an invaluable opportunity to discover a number of exciting and innovative companies.
For more information about the Roth Virtual Healthcare Private Company Forum, visit
www.roth.com/healthcareprivateday
